Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization

PURPOSE: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 (T2) inflammation in multiple diseases. In phase 3 QUEST (NCT02414854), dupilumab vs placebo significantly reduced asthma exacerbation rates (AER) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Corren, Jonathan, Jackson, David J, Casale, Thomas B, Borish, Larry, Rabe, Klaus F, Busse, William W, Maspero, Jorge F, Jackson, Daniel J, Daizadeh, Nadia, Altincatal, Arman, Radwan, Amr, Khodzhayev, Angela, Djandji, Michel, Jacob-Nara, Juby A, Rowe, Paul J, Deniz, Yamo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007984/
https://www.ncbi.nlm.nih.gov/pubmed/36915284
http://dx.doi.org/10.2147/JAA.S385645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007984/
https://www.ncbi.nlm.nih.gov/pubmed/36915284
http://dx.doi.org/10.2147/JAA.S385645

Ejemplares similares